513 related articles for article (PubMed ID: 17697836)
1. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ
Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836
[TBL] [Abstract][Full Text] [Related]
2. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
3. Releasing growth factors from activated human platelets after chitosan stimulation: a possible bio-material for platelet-rich plasma preparation.
Shen EC; Chou TC; Gau CH; Tu HP; Chen YT; Fu E
Clin Oral Implants Res; 2006 Oct; 17(5):572-8. PubMed ID: 16958699
[TBL] [Abstract][Full Text] [Related]
4. Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.
Schneider DJ; Sobel BE
Coron Artery Dis; 2009 Mar; 20(2):175-8. PubMed ID: 19194284
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of platelet function, a method comparison.
Nylander S; Johansson K; Van Giezen JJ; Lindahl TL
Platelets; 2006 Feb; 17(1):49-55. PubMed ID: 16308187
[TBL] [Abstract][Full Text] [Related]
6. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
Kassassir H; Siewiera K; Sychowski R; Watała C
Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
[TBL] [Abstract][Full Text] [Related]
7. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
9. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
10. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
11. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
[TBL] [Abstract][Full Text] [Related]
12. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
13. Detection of activated platelets and platelet-leukocyte aggregates in horses.
Weiss DJ; Evanson OA
Am J Vet Res; 1997 Aug; 58(8):823-7. PubMed ID: 9256963
[TBL] [Abstract][Full Text] [Related]
14. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.
Zhao L; Gaudry L; Dunkley S; Brighton T; Guo ZX; Ye ZL; Luo RZ; Chesterman CN
Platelets; 2008 Feb; 19(1):24-31. PubMed ID: 18231935
[TBL] [Abstract][Full Text] [Related]
15. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
Kempton CL; Hoffman M; Roberts HR; Monroe DM
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):861-6. PubMed ID: 15653564
[TBL] [Abstract][Full Text] [Related]
16. Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function.
Natarajan P; May JA; Sanderson HM; Zabe M; Spangenberg P; Heptinstall S
Platelets; 2000 Dec; 11(8):467-76. PubMed ID: 11177446
[TBL] [Abstract][Full Text] [Related]
17. Protective mechanisms of adenosine 5'-monophosphate in platelet activation and thrombus formation.
Fuentes E; Badimon L; Caballero J; Padró T; Vilahur G; Alarcón M; Pérez P; Palomo I
Thromb Haemost; 2014 Mar; 111(3):491-507. PubMed ID: 24306059
[TBL] [Abstract][Full Text] [Related]
18. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
Jagroop IA; Mikhailidis DP
Clin Appl Thromb Hemost; 2008 Jul; 14(3):295-302. PubMed ID: 18445610
[TBL] [Abstract][Full Text] [Related]
19. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation.
Craft RM; Chavez JJ; Bresee SJ; Wortham DC; Cohen E; Carroll RC
J Lab Clin Med; 2004 May; 143(5):301-9. PubMed ID: 15122174
[TBL] [Abstract][Full Text] [Related]
20. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood.
Rajasekhar D; Kestin AS; Bednarek FJ; Ellis PA; Barnard MR; Michelson AD
Thromb Haemost; 1994 Dec; 72(6):957-63. PubMed ID: 7740470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
